As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data

A few days after Bayer ended its collaboration with Ionis, the biotech is trudging forward with another program it sold to Roche over the summer.

Ionis revealed new details on a Phase II trial for IONIS-FB-LRx, an antisense program designed to treat immunoglobulin A (IgA) nephropathy, which hit its primary endpoint earlier this year. The drug is slated to enter Phase III in the first half of 2023, with Roche — having acquired the rights in July — heading up all clinical development efforts